Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 06, 2025 15:30 ET | Source: BioNTech SE

BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer

Gotistobart demonstrated a clinically meaningful overall survival benefit compared to standard chemotherapy and a manageable safety profile in sqNSCLC
December 06, 2025 09:30 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition

Objective response rate (ORR) of 83% including two complete responses in CLL patients in Phase 1a study with median progression free survival (PFS) of 22.1 months across all doses tested Emerging...
December 06, 2025 09:30 ET | Source: Genmab A/S

Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)

Media ReleaseCOPENHAGEN, Denmark; December 6, 2025 New two- and three-year EPCORE® NHL-2 follow-up data evaluating epcoritamab in combination with standard of care regimens demonstrate remission in...
December 06, 2025 08:30 ET | Source: Adaptive Biotechnologies

Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting

Adaptive announces deep interventional use of clonoSEQ across abstracts at ASH
December 06, 2025 08:00 ET | Source: Bicara Therapeutics Inc.

Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026

Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety profile comparable to 1500mg QW dose, further derisking pivotal FORTIFI-HN01 study...
December 05, 2025 22:11 ET | Source: Junshi Biosciences

Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients

Promising long-term survival results from toripalimab's JUPITER-02 and JUPITER-06 presented at the ESMO ASIA
December 05, 2025 00:58 ET | Source: Ipsen Pharma

Ipsen provides update on legacy of Henri Beaufour

PARIS, FRANCE, 5 December 2025, Ipsen (Euronext: IPN; ADR: IPSEY) has been informed that the shares of Beech Tree will be transferred to the Alasol Foundation, in accordance with the wishes of Mr....
December 04, 2025 20:00 ET | Source: Transcenta

Transcenta Therapeutics Presents Updated Efficacy Data from the Phase I/II Transtar102 Trial of Osemitamab plus Nivolumab and CAPOX in First-Line G/GEJ Cancer at ESMO Asia

PRINCETON, N.J. and SUZHOU, China, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Transcenta Holding Limited (HKEX: 06628) ("Transcenta Therapeutics"), a global clinical stage biopharmaceutical company with...
December 04, 2025 09:30 ET | Source: Custom Market Insights

[Latest] Global 4D Printing in Healthcare Market Size/Share Worth USD 14240 Million by 2034 at a 84.6% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USa, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “4D Printing in Healthcare Market Size, Trends and Insights By Component...
December 04, 2025 08:30 ET | Source: SNS Insider pvt ltd

Preclinical CRO Market Size to Reach USD 11.54 Billion by 2033, Driven by Rising Outsourcing and Growth in Advanced Preclinical Models – SNS Insider

Global Preclinical CRO Market projected to grow to USD 11.54 Billion by 2033 due to rising outsourcing, advanced models, and expanding drug pipelines.